A detailed history of Assetmark, Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Assetmark, Inc holds 4 shares of CRSP stock, worth $198. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4
Previous 11 63.64%
Holding current value
$198
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$51.17 - $68.18 $358 - $477
-7 Reduced 63.64%
4 $0
Q1 2024

May 06, 2024

BUY
$60.67 - $89.12 $667 - $980
11 New
11 $0
Q2 2022

Aug 03, 2022

SELL
$43.23 - $73.83 $2,377 - $4,060
-55 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$53.19 - $79.24 $2,925 - $4,358
55 New
55 $3,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.87B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.